Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases

References

• Burisch J, Zhao M, Odes S, et al. The cost of inflammatory bowel disease in high-income settings: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 2023;8(5):458–492. doi:10.1016/S2468-1253(23)00003-1
   PubMed Web of Science ®Google Scholar
• Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–434. doi:10.1038/nature06005
   PubMed Web of Science ®Google Scholar
• Laredo V, García-Mateo S, Martínez-Domínguez SJ, López de la Cruz J, Gargallo-Puyuelo CJ, Gomollón F. Risk of cancer in patients with inflammatory bowel diseases and keys for patient management. Cancers. 2023;15(3):871. doi:10.3390/cancers15030871
   PubMed Web of Science ®Google Scholar
• Spinelli A, Bonovas S, Burisch J, et al. ECCO Guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohn’s Colitis. 2022;16(2):179–189. doi:10.1093/ecco-jcc/jjab177
   Google Scholar
• Kotla NG, Rochev Y. IBD disease-modifying therapies: insights from emerging therapeutics. Trends Mol Med. 2023;29(3):241–253. doi:10.1016/j.molmed.2023.01.001
   PubMed Web of Science ®Google Scholar
• Flower RJ, Rothwell NJ. Lipocortin-1: cellular mechanisms and clinical relevance. Trends Pharmacol Sci. 1994;15(3). doi:10.1016/0165-6147(94)90281-X
   PubMed Web of Science ®Google Scholar
• Moss SE, Morgan RO. The annexins. Genome Biol. 2004;5(4):219. doi:10.1186/gb-2004-5-4-219
   PubMed Web of Science ®Google Scholar
• Perretti M, D’Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol. 2009. doi:10.1038/nri2470
   PubMed Web of Science ®Google Scholar
• Perretti M, Dalli J. Resolution pharmacology: focus on pro-resolving annexin A1 and lipid mediators for therapeutic innovation in inflammation. Annu Rev Pharmacol Toxicol. 2023;63(1):449–469. doi:10.1146/annurev-pharmtox-051821-042743
   PubMedGoogle Scholar
• Machado ID, Spatti M, Hastreiter A, et al. Annexin A1 Is a physiological modulator of neutrophil maturation and recirculation acting on the CXCR4/CXCL12 Pathway. J Cell Physiol. 2016;231(11):2418–2427. doi:10.1002/jcp.25346
   PubMed Web of Science ®Google Scholar
• Sheikh M, Solito E. Annexin A1: uncovering the many talents of an old protein. Int J Mol Sci. 2018;19(4):1045. doi:10.3390/ijms19041045
   PubMed Web of Science ®Google Scholar
• Foo SL, Yap G, Cui J, Lim LHK. Annexin-A1 – a Blessing Or A Curse In Cancer? Trends Mol Med. 2019;25(4):315–327. doi:10.1016/j.molmed.2019.02.004
   PubMed Web of Science ®Google Scholar
• Vergnolle N, Comera C, Bueno L. Annexin 1 is overexpressed and specifically secreted during experimentally induced colitis in rats. Eur J Biochem. 1995;232(2):603–610. doi:10.1111/j.1432-1033.1995.tb20850.x
   PubMedGoogle Scholar
• Vergnolle N, Pagés P, Guimbaud R, et al. Annexin 1 is secreted in situ during ulcerative colitis in humans. Inflamm Bowel Dis. 2004;10(5):584–592. doi:10.1097/00054725-200409000-00013
   PubMed Web of Science ®Google Scholar
• Sena A, Grishina I, Thai A, et al. Dysregulation of Anti-Inflammatory Annexin A1 expression in progressive crohns disease. PLoS One. 2013. doi:10.1371/journal.pone.0076969
   Web of Science ®Google Scholar
• de Paula-Silva M, Barrios BE, Macció-Maretto L, et al. Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis. Biochem Pharmacol. 2016;115:104–113. doi:10.1016/j.bcp.2016.06.012
   PubMed Web of Science ®Google Scholar
• Reischl S, Troger J, Jesinghaus M, et al. Annexin A1 expression capacity as a determinant for disease severity in crohn’s disease. Dig Dis. 2020;38(5):398–407. doi:10.1159/000505910
   PubMed Web of Science ®Google Scholar
• Babbin BA, Laukoetter MG, Nava P, et al. Annexin A1 regulates intestinal mucosal injury, inflammation, and repair. J Immunol. 2008;181(7):5035–5044. doi:10.4049/jimmunol.181.7.5035
   PubMed Web of Science ®Google Scholar
• Wentworth CC, Jones RM, Kwon YM, Nusrat A, Neish AS. Commensal-epithelial signaling mediated via formyl peptide receptors. Am J Pathol. 2010;177(6):2782–2790. doi:10.2353/ajpath.2010.100529
   PubMed Web of Science ®Google Scholar
• Vong L, Ferraz JGP, Dufton N, et al. Up-Regulation of Annexin-A1 and Lipoxin A4 in Individuals with Ulcerative Colitis May Promote Mucosal Homeostasis. PLoS One. 2012;7(6):e39244. doi:10.1371/journal.pone.0039244
   PubMed Web of Science ®Google Scholar
• Birkl D, O’Leary MN, Quiros M, et al. Formyl peptide receptor 2 regulates monocyte recruitment to promote intestinal mucosal wound repair. FASEB J. 2019;33(12):13632–13643. doi:10.1096/fj.201901163R
   PubMed Web of Science ®Google Scholar
• de Paula-Silva M, da Rocha GHO, Broering MF, et al. Formyl peptide receptors and Annexin A1: complementary mechanisms to infliximab in murine experimental colitis and crohn’s disease. Front Immunol. 2021:12. doi:10.3389/fimmu.2021.714138
   Web of Science ®Google Scholar
• Galvão I, Vago JP, Barroso LC, et al. Annexin A1 promotes timely resolution of inflammation in murine gout. Eur J Immunol. 2017;47(3):585–596. doi:10.1002/eji.201646551
   PubMed Web of Science ®Google Scholar
• Alhasan H, Terkawi MA, Matsumae G, et al. Inhibitory role of Annexin A1 in pathological bone resorption and therapeutic implications in periprosthetic osteolysis. Nat Commun. 2022;13(1):3919. doi:10.1038/s41467-022-31646-0
   PubMed Web of Science ®Google Scholar
• Leoni G, Alam A, Neumann P-A, et al. Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest. 2013;123(1):443–454. doi:10.1172/JCI65831
   PubMed Web of Science ®Google Scholar
• Leoni G, Gripentrog J, Lord C, et al. Human neutrophil formyl peptide receptor phosphorylation and the mucosal inflammatory response. J Leukoc Biol. 2015;97(1):87–101. doi:10.1189/jlb.4a0314-153r
   PubMed Web of Science ®Google Scholar
• Li C, Zhao Y, Cheng J, et al. A proresolving peptide nanotherapy for site-specific treatment of inflammatory bowel disease by regulating proinflammatory microenvironment and gut microbiota. Adv Sci. 2019;6(18). doi:10.1002/advs.201900610
   Web of Science ®Google Scholar
• Reischl S, Lee JH, Miltschitzky JRE, et al. Ac2-26-nanoparticles induce resolution of intestinal inflammation and anastomotic healing via inhibition of NF-κB signaling in a model of perioperative colitis. Inflamm Bowel Dis. 2021;27(9):1379–1393. doi:10.1093/ibd/izab008
   PubMed Web of Science ®Google Scholar
• Broering MF, Leão M, da Rocha GHO, et al. Development of Annexin A1-surface-functionalized metal-complex multi-wall lipid core nanocapsules and effectiveness on experimental colitis. Eur J Pharm Biopharm. 2022;181:49–59. doi:10.1016/j.ejpb.2022.10.022
   PubMed Web of Science ®Google Scholar
• Patra CN, Priya R, Swain S, Kumar Jena G, Panigrahi KC, Ghose D. Pharmaceutical significance of Eudragit: a review. Futur J Pharm Sci. 2017;3(1):33–45. doi:10.1016/j.fjps.2017.02.001
   Web of Science ®Google Scholar
• Gao C, Yu S, Zhang X, et al. Dual Functional Eudragit® S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis. Int J Nanomed. 2021;16:1405–1422. doi:10.2147/IJN.S291090
   PubMed Web of Science ®Google Scholar
• Matos JR, Mercuri LP, Kruk M, Jaroniec M. Toward the synthesis of extra-large-pore MCM-41 analogues. Chem Mater. 2001;13(5):1726–1731. doi:10.1021/cm000964p
   Web of Science ®Google Scholar
• Appiah-Ntiamoah R, Chung WJ, Kim H. A highly selective SBA-15 supported fluorescent “turn-on” sensor for the fluoride anion. New J Chem. 2015;39(7):5570–5579. doi:10.1039/c5nj00495k
   Web of Science ®Google Scholar
• Sayed IM, Ibeawuchi SR, Lie D, et al. The interaction of enteric bacterial effectors with the host engulfment pathway control innate immune responses. Gut Microbes. 2021;13(1). doi:10.1080/19490976.2021.1991776
   PubMed Web of Science ®Google Scholar
• Das S, Sarkar A, Choudhury SS, et al. Engulfment and cell motility protein 1 (ELMO1) has an essential role in the internalization of salmonella typhimurium into enteric macrophages that impact disease outcome. Cmgh. 2015;1(3):311–324. doi:10.1016/j.jcmgh.2015.02.003
   Google Scholar
• van Meerloo J, Kaspers GJL, Cloos J. Cell sensitivity assays: the MTT ASSAY. In. 2011:237–245. doi:10.1007/978-1-61779-080-5_20
   PubMedGoogle Scholar
• Sayed IM, Sahan AZ, Venkova T, et al. Helicobacter pylori infection downregulates the DNA glycosylase NEIL2, resulting in increased genome damage and inflammation in gastric epithelial cells. J Biol Chem. 2020;295(32):11082–11098. doi:10.1074/jbc.ra119.009981
   PubMed Web of Science ®Google Scholar
• Sharma A, Lee J, Fonseca AG, et al. E-cigarettes compromise the gut barrier and trigger inflammation. iScience. 2021;24(2):102035. doi:10.1016/j.isci.2021.102035
   PubMed Web of Science ®Google Scholar
• Morrison ID, Grabowski EF, Herb CA. Improved techniques for particle size determination by quasi-elastic light scattering. Langmuir. 1985;1(4):496–501. doi:10.1021/la00064a016
   Web of Science ®Google Scholar
• Glatter O. Data evaluation in small angle scattering: calculation of the radial electron density distribution by means of indirect Fourier transformation. Acta Phys Austriaca. 1977;47(1–2):83–102.
   Google Scholar
• Pinto Oliveira CL. Investigating macromolecular complexes in solution by small angle X-ray scattering. In Current Trends in X-Ray Crystallography. InTech; 2011. doi10.5772/30730
   Google Scholar
• Martinez RM, Oseliero Filho PL, Gerbelli BB, et al. Influence of the mixtures of vegetable oil and vitamin E over the microstructure and rheology of organogels. Gels. 2022;8(1):36. doi:10.3390/gels8010036
   PubMed Web of Science ®Google Scholar
• Losito DW, Lopes PS, Ueoka AR, et al. Biocomposites based on SBA-15 and papain: characterization, enzymatic activity and cytotoxicity evaluation. Microporous Mesoporous Mater. 2021;325:111316. doi:10.1016/j.micromeso.2021.111316
   Web of Science ®Google Scholar
• Losito DW, de Araujo DR, Bezzon VDN, et al. Mesoporous Silica–Fe3O4 nanoparticle composites as potential drug carriers. ACS Appl Nano Mater. 2021;4(12):13363–13378. doi:10.1021/acsanm.1c02861
   Web of Science ®Google Scholar
• Zhao D, Feng J, Huo Q, et al. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 Angstrom Pores. Science. 1998;279(5350):548–552. doi:10.1126/science.279.5350.548
   PubMed Web of Science ®Google Scholar
• Kruk M, Jaroniec M, Ko CH, Ryoo R. Characterization of the Porous Structure of SBA-15. Chem Mater. 2000;12(7):1961–1968. doi:10.1021/cm000164e
   Web of Science ®Google Scholar
• Li L, Liu T, Fu C, Tan L, Meng X, Liu H. Biodistribution, excretion, and toxicity of mesoporous silica nanoparticles after oral administration depend on their shape. Nanomed Nanotechnol Biol Med. 2015;11(8):1915–1924. doi:10.1016/j.nano.2015.07.004
   PubMed Web of Science ®Google Scholar
• Zhang F, Du Y, Zheng J, et al. Oral Administration of Multistage Albumin Nanomedicine Depots (MANDs) for Targeted Efficient Alleviation of Chronic Inflammatory Diseases. Adv Funct Mater. 2023;33(9):2211644. doi:10.1002/adfm.202211644
   Web of Science ®Google Scholar
• Mariano-Neto F, Matos JR, Cides da Silva LC, et al. Physical properties of ordered mesoporous SBA-15 silica as immunological adjuvant. J Phys D Appl Phys. 2014;47(42):425402. doi:10.1088/0022-3727/47/42/425402
   Web of Science ®Google Scholar
• Zhao D, Huo Q, Feng J, Chmelka BF, Stucky GD. Nonionic triblock and star diblock copolymer and oligomeric surfactant syntheses of highly ordered, hydrothermally stable, mesoporous silica structures. J Am Chem Soc. 1998;120(24):6024–6036. doi:10.1021/ja974025i
   Web of Science ®Google Scholar
• Scaramuzzi K, Oliveira DCA, Carvalho LV, et al. Nanostructured SBA-15 silica as an adjuvant in immunizations with hepatitis B vaccine. Einstein. 2011;9(4):436–441. doi:10.1590/s1679-45082011ao2162
   PubMedGoogle Scholar
• Xu C, Lei C, Yu C. Mesoporous Silica Nanoparticles for Protein Protection and Delivery. Front Chem. 2019;7. doi:10.3389/fchem.2019.00290
   Web of Science ®Google Scholar
• Mechler-Dreibi ML, Almeida HMS, Sonalio K, et al. Oral vaccination of piglets against Mycoplasma hyopneumoniae using silica SBA-15 as an adjuvant effectively reduced consolidation lung lesions at slaughter. Sci Rep. 2021;11(1):22377. doi:10.1038/s41598-021-01883-2
   PubMed Web of Science ®Google Scholar
• Rosenholm JM, Sahlgren C, Lindén M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles – opportunities & challenges. Nanoscale. 2010;2(10):1870. doi:10.1039/c0nr00156b
   PubMed Web of Science ®Google Scholar
• Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010;6(16):1794–1805. doi:10.1002/smll.201000538
   PubMed Web of Science ®Google Scholar
• Sarkar S, Ekbal Kabir M, Kalita J, Manna P. Mesoporous silica nanoparticles: drug delivery vehicles for antidiabetic molecules. ChemBioChem. 2023;24(7). doi:10.1002/cbic.202200672
   Google Scholar
• Trezena AG, Oseliero Filho PL, Cides da Silva LC, et al. Adjuvant effect of mesoporous silica SBA-15 on anti-diphtheria and anti-tetanus humoral immune response. Biologicals. 2022;80:18–26. doi:10.1016/j.biologicals.2022.10.001
   PubMed Web of Science ®Google Scholar
• Rasmussen MK, Kardjilov N, Oliveira CLP, et al. 3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15. Sci Rep. 2019;9(1):6106. doi:10.1038/s41598-019-42645-5
   PubMedGoogle Scholar
• Bannunah AM, Vllasaliu D, Lord J, Stolnik S. Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge. Mol Pharm. 2014;11(12):4363–4373. doi:10.1021/mp500439c
   PubMed Web of Science ®Google Scholar
• Thakral S, Thakral NK, Majumdar DK. Eudragit®: a technology evaluation. Expert Opin Drug Deliv. 2013;10(1):131–149. doi:10.1517/17425247.2013.736962
   PubMed Web of Science ®Google Scholar
• Barbosa JAC, Abdelsadig MSE, Conway BR, Merchant HA. Using zeta potential to study the ionisation behaviour of polymers employed in modified-release dosage forms and estimating their pKa. Int J Pharm X. 2019;1:100024. doi:10.1016/j.ijpx.2019.100024
   PubMedGoogle Scholar
• Beloqui A, Coco R, Alhouayek M, et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int J Pharm. 2013;454(2). doi:10.1016/j.ijpharm.2013.05.017
   PubMedGoogle Scholar
• Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol. 2020;11:1–22. doi:10.3389/fphar.2020.00524
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. doi:10.1038/s41573-020-0090-8
   PubMed Web of Science ®Google Scholar
• Cooray SN, Gobbetti T, Montero-Melendez T, et al. Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci. 2013;110(45). doi:10.1073/pnas.1308253110
   PubMed Web of Science ®Google Scholar
• Langguth P, Bohner V, Heizmann J, et al. The challenge of proteolytic enzymes in intestinal peptide delivery. J Control Release. 1997;46(1–2):39–57. doi:10.1016/S0168-3659(96)01586-6
   Web of Science ®Google Scholar
• Hayhoe RPG, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood. 2006;107(5):2123–2130. doi:10.1182/blood-2005-08-3099
   PubMed Web of Science ®Google Scholar
• Lim LHK, Pervaiz S. Annexin 1: the new face of an old molecule. FASEB J. 2007;21(4):968–975. doi:10.1096/fj.06-7464rev
   PubMed Web of Science ®Google Scholar
• Girol AP, Mimura KKO, Drewes CC, et al. Anti-inflammatory mechanisms of the annexin A1 protein and its mimetic peptide Ac2-26 in models of ocular inflammation in vivo and in vitro. J Immunol. 2013;190(11). doi:10.4049/jimmunol.1202030
   PubMed Web of Science ®Google Scholar
• Walther A, Riehemann K, Gerke V. A novel ligand of the formyl peptide receptor. Mol Cell. 2000;5(5):831–840. doi:10.1016/S1097-2765(00)80323-8
   PubMed Web of Science ®Google Scholar
• Maderna P, Yona S, Perretti M, Godson C. Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac2–26. J Immunol. 2005;174(6):3727–3733. doi:10.4049/jimmunol.174.6.3727
   PubMed Web of Science ®Google Scholar
• Sugimoto MA, Vago JP, Teixeira MM, Sousa LP. Annexin A1 and the resolution of inflammation: modulation of neutrophil recruitment, apoptosis, and clearance. J Immunol Res. 2016;2016. doi:10.1155/2016/8239258
   PubMed Web of Science ®Google Scholar
• Cristante E, McArthur S, Mauro C, et al. Identification of an essential endogenous regulator of blood–brain barrier integrity, and its pathological and therapeutic implications. Proc Natl Acad Sci. 2013;110(3):832–841. doi:10.1073/pnas.1209362110
   PubMed Web of Science ®Google Scholar
• Park J-C, Baik SH, Han S-H, et al. Annexin A1 restores Aβ 1-42 -induced blood-brain barrier disruption through the inhibition of RhoA-ROCK signaling pathway. Aging Cell. 2017;16(1):149–161. doi:10.1111/acel.12530
   PubMed Web of Science ®Google Scholar
• Lacerda JZ, Drewes CC, Mimura KKO, et al. Annexin A12–26 treatment improves skin heterologous transplantation by modulating inflammation and angiogenesis processes. Front Pharmacol. 2018:9. doi:10.3389/fphar.2018.01015
   PubMed Web of Science ®Google Scholar
• Hebeda CB, Sandri S, Benis CM, et al. Annexin A1/Formyl peptide receptor pathway controls uterine receptivity to the blastocyst. Cells. 2020;9(5). doi:10.3390/cells9051188
   PubMed Web of Science ®Google Scholar
• Sheikh MH, Errede M, d’Amati A, et al. Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood‐brain barrier: therapeutic avenues. FASEB J. 2022;36(1). doi:10.1096/fj.202101297R
   PubMed Web of Science ®Google Scholar
• Lyngstadaas AV, Olsen MV, Bair JA, et al. Pro-resolving mediator annexin a1 regulates intracellular Ca2+ and mucin secretion in cultured goblet cells suggesting a new use in inflammatory conjunctival diseases. Front Immunol. 2021:12. doi:10.3389/fimmu.2021.618653
   Web of Science ®Google Scholar